JAMA Internal Medicine —The Year in Review, 2020

We welcome the promise of 2021 —to start to get control of the global pandemic via vaccinations against SARS-CoV-2 and effective public health measures and hopefully let the country get back to the hard work of promoting high-value health care that is affordable and available to all Americans. As a new US administration with si gnificant health care expertise begins work, we are hopeful to see progress on complex issues, such as value-based payment, drug pricing, and transparency issues, to name a few.We are interested to learn what the impact of sharply reduced elective health care visits and reduced cancer screenings wil l be as we track rates of breast cancer, lung cancer, heart disease, and many others in the coming decade. We are now in the 10th year of the JAMA Internal Medicine Less is More series and are pleased to see international attention to the harms of overdiagnosis and overtreatment and on programs to i ncrease high-value care. Of course, our work is far from done, as health care costs continue to rise much faster than the gross domestic product and approach one-fifth of the US economy.
Source: JAMA Internal Medicine - Category: Internal Medicine Source Type: research